Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Interest Expense : HK$-249 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Yichang HEC ChangJiang Pharmaceutical Co's interest expense for the six months ended in Dec. 2023 was HK$ -100 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-249 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Yichang HEC ChangJiang Pharmaceutical Co's Operating Income for the six months ended in Dec. 2023 was HK$ 1,459 Mil. Yichang HEC ChangJiang Pharmaceutical Co's Interest Expense for the six months ended in Dec. 2023 was HK$ -100 Mil. Yichang HEC ChangJiang Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 was 14.63. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Yichang HEC ChangJiang Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Interest Expense Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-227.56

-289.49

-298.53

-314.52

-248.72

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial														-152.46	-160.61	-161.51	-149.05	-99.68

Yichang HEC ChangJiang Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-249 Mil.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Yichang HEC ChangJiang Pharmaceutical Co's Interest Expense for the six months ended in Dec. 2023 was HK$-100 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$1,459 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$317 Mil.

Yichang HEC ChangJiang Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	1458.611	/	-99.676
	=	14.63

The higher the ratio, the stronger the company's financial strength is.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN

Website

http://www.hec-changjiang.com

Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.

Executives

Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si	2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Meilan	2201 Interest of corporation controlled by you
Hua Xiaoyi	2201 Interest of corporation controlled by you
Zhang Yushuai	2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd.	2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p.	2201 Interest of corporation controlled by you
Blackstone Inc.	2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p.	2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p.	2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd.	2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines